Hepatitis C Virus and Therapeutics: A Global Strategic Business Report
San Jose, CA (PRWEB) April 14, 2009
Bucking the trend witnessed for all these years of meager clinical outcomes owing to lack of superior therapies, research & development in hepatitis C virus therapeutics market is on the verge of a major breakthrough. The Hepatitis C Virus (HCV) therapeutics development landscape continues to inflate and currently possesses three compounds in Phase III clinical studies, several novel therapies in Phase II and Phase I pipeline, and numerous new compounds in animal-stage study and research stages. Along with immunomodulators, long acting/oral interferons, and direct acting anti-viral therapies, new compounds represented by several other drug categories, including Polymerase/Protease Inhibitors, MicroRNA, TLR9 agonists, NS5A Inhibitors, Cyclophilin inhibitors, A3AR Agonists, and vaccines among others, would be successfully developed to expand the scope of HCV treatment.
Global market for HCV therapeutics is projected to reach $9.1 billion by 2015, as stated by Global Industry Analysts, Inc. Key drivers include rising number of treatment-obliged chronic hepatitis C patients with advanced chronic stage disorders and liver disease, and expected increase in relapser/non-responder patient population, who need re-treatment in majority of cases. However, growth in the market is expected to face hindrances due to the silent nature of the infection that never insists on treatment till it reaches end-stage level, low rates in infection diagnosis and referral, and decreasing rates of incidences especially in developed countries, which represent a substantial portion for the market.
For the past several years, the market for HCV therapeutics has been under control of two players, Swedish drug major, F. Hoffmann-La Roche Limited (Roche) and the US-based Pharma giant, Schering-Plough Corporation (Schering). However, there exists an immediate need for advanced new treatments as current therapies are effective in only 50% of patients and are also associated with several significant side effects.
Major players in the global HCV therapeutics market include Abbott Diagnostics, Achillion Pharmaceuticals, Anadys Pharmaceuticals, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, GlaxoSmithKline, Hayashibara Biochemical Labs, Human Genome Sciences, Idenix Pharmaceuticals, Innogenetics NV, InterMune, Intarcia Therapeutics, Medivir AB, Merck, Novartis, Pfizer, Schering-Plough, Tibotec Pharmaceuticals, Tripep, Toray Industries, Valeant Pharmaceuticals International, and Vertex Pharmaceuticals, among others.
The report titled "Hepatitis C Virus and Therapeutics: A Global Strategic Business Report" published by Global Industry Analysts, Inc., provides a comprehensive review of industry overview, key market trends, clinical trials, profiles of major players, and recent industry activity. The report analyzes market data and provides analytics in value sales for Global Hepatitis C therapeutics market.
For more details about this research report, please visit http://www.strategyr.com/Hepatitis_C_Virus_and_Therapeutics_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site http://www.StrategyR.com